Targeting CDK4 in Melanoma

通过开发驱动癌症生长的癌基因抑制剂，在癌症治疗方面取得了重大进展。该应用程序将测试该方法是否可用于激活CDK4癌基因的黑色素瘤，CDK4癌基因在50%以上的黑色素瘤中被激活。我们将确定哪些黑素瘤患者对这种方法反应最好，并了解为什么一些黑素瘤而其他黑素瘤没有反应，为CDK4抑制剂的临床试验提供科学框架。

Major progress has been made in the treatment of cancer by the development of inhibitors of oncogenes that drive cancer growth. This application will test whether this approach can be used for melanomas with activation of the CDK4 oncogene that becomes activated in over 50% of melanomas. We will indentify which patients melanomas respond best to this approach and understand why some melanomas but not other responds providing the scientific framework for clinical trials of CDK4 inhibitors.